A specialized, preclinical-stage biotech company, Inversago Pharma develops new generations of peripherally-restricted cannabinoid-1 receptor (CB1) inverse agonists/ antagonists for the treatment of Prader-Willi Syndrome, diabetes, obesity and other metabolic disorders such as non-alcoholic steatohepatitis (NASH). 

Pharmaceutical

Inversago Pharma

Karine Lalonde

Michael D. Harvey

Jianmin Duan

Annie Chevrier

Jean-Daniel Bélanger

Micheline Beauvais

Jeremy Green

Adriana Di Marco

Genevieve Gaucher

Michèle Desjardins

Research and Development

Leadership Team

Regulatory and Compliance

��

Teams at Inversago Pharma

Research and Development

Leadership Team

Regulatory and Compliance

��������

Teams at Inversago Pharma

Research and Development

Leadership Team

Regulatory and Compliance

��